Clinical trial landscape for pneumonia: Evolving agents against bacterial pathogens
Objective: Pneumonia remains a critical global health challenge, with antimicrobial resistance fundamentally reshaping therapeutic paradigms. This study aimed to characterize global trends in pneumonia-related clinical trials and assess the pipeline response to escalating antimicrobial resistance ch...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971225001894 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective: Pneumonia remains a critical global health challenge, with antimicrobial resistance fundamentally reshaping therapeutic paradigms. This study aimed to characterize global trends in pneumonia-related clinical trials and assess the pipeline response to escalating antimicrobial resistance challenges. Methods: We conducted comprehensive analysis using the INFORMA Database, searching MeSH terms ‘Community-acquired pneumonia’ and ‘Hospital-acquired pneumonia’ while restricting inclusion to bacterial infections. Interventional clinical trials investigating therapeutic agents for bacterial pneumonia were included. Data collection encompassed trial status, primary drugs, mechanisms of action, patient demographics, and completion dates. Statistical analyses included Cochran-Armitage trend tests for temporal patterns, and Chi-square goodness of fit test for age-stratified analyses. Results: A total of 2,448 pneumonia-related clinical trials were identified across 113 countries from 1991 to 2024. Phase I trials demonstrated pronounced acceleration, increasing from 3.00 trials per year (1991-2000) to 14.82 trials per year (2020-2024). Five therapeutic mechanisms dominated research: cell wall synthesis inhibitors (24.5%), ribosomal subunit inhibitors (13.5%), DNA topoisomerase inhibitors (12.8%), beta-lactamase inhibitors (9.3%), and cell membrane-related mechanisms (7.9%). Agestratified analysis revealed significant disparities, with elderly-specific trials comprising only 2.8% despite higher disease burden. Conclusion: This analysis reveals accelerating early-phase drug development in response to antimicrobial resistance challenges. While traditional mechanisms remain dominant, novel therapeutic approaches demonstrate promising diversification strategies, though critical gaps persist in elderly-specific drug development. |
|---|---|
| ISSN: | 1201-9712 |